8-K: BriaPro Reports Increased Losses, Going Concern Doubts

BriaPro Therapeutics, a BriaCell subsidiary, reported increased losses for the year ended July 31, 2025, while advancing its pre-clinical immuno-oncology programs, facing significant going concern doubts.

Summary

• BriaPro Therapeutics Corp., a two-thirds (2/3) owned subsidiary of BriaCell Therapeutics Corp., filed its Consolidated Financial Statements and Management's Discussion and Analysis for the period ended July 31, 2025.
• The company incurred a net loss of $740,216 for the year ended July 31, 2025, an increase from $420,287 in the prior year.
• Accumulated deficit since incorporation reached $1,180,425 as of July 31, 2025.
• Research and development expenses increased to $472,982 for the year ended July 31, 2025, up from $272,249 in 2024, primarily due to increased pre-clinical consulting fees.
• General and administrative expenses rose to $235,132 for the year ended July 31, 2025, from $197,445 in 2024, driven by increased spending on shareholder communication and filing fees.
• BriaPro is currently in the pre-clinical research stage, has not commenced commercial operations, and is entirely dependent on BriaCell to finance its operations.
• A material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern due to accumulated losses and the need for future financing.
• The company is developing Bria-TILsRx (multi-specific binding reagents), PKC inhibitors, and anti-B7-H3 antibodies for cancer, leveraging artificial intelligence (AI) in drug candidate selection.
• Provisional patent applications were filed for the TILsRx platform on July 29, 2025, and for novel anti-B7-H3 antibodies on April 10, 2025, with a corresponding PCT international patent filed in May 2025.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues, increasing losses, and a material uncertainty regarding its ability to continue as a going concern, relying entirely on its parent for funding. While its pre-clinical pipeline and AI strategy show potential, the immediate financial health is very weak, indicating high risk.

Positives

• Advancement of multiple pre-clinical immuno-oncology programs, including Bria-TILsRx, PKC inhibitors, and anti-B7-H3 antibodies.
• Filed provisional patent applications for the TILsRx platform on July 29, 2025, and for novel anti-B7-H3 antibodies on April 10, 2025, with a PCT international patent filed in May 2025.
• Strategic research collaboration with Receptor.AI for small-molecule drug candidate identification, leveraging AI technology to accelerate drug discovery.
• Management believes its anti-B7-H3 antibody has superior target-binding potential compared to other existing antibodies.
• PKC inhibitors have shown activity against multiple RAS transformed tumors and potentially offer a safe treatment for up to 90% of human cancers.
• The Bria-TILsRx platform is quadrivalent, designed to enhance specific targeting of tumor cells and potent activation of T cells, potentially offering advantages over current bi-specific T cell engagers.

Negatives

• Incurred a significant net loss of $740,216 for the year ended July 31, 2025, an increase from $420,287 in the prior year.
• Accumulated deficit since incorporation totals $1,180,425 as of July 31, 2025.
• Currently in the pre-clinical research stage with no commercial operations or revenue generation.
• Negative working capital worsened to $1,148,492 as of July 31, 2025, from $455,649 in 2024.
• A material uncertainty exists regarding the company's ability to continue as a going concern due to accumulated losses and dependence on future financing.
• The company is entirely dependent on BriaCell to finance its operations until additional financing is secured.
• Cash and cash equivalents remained at $1 as of both July 31, 2025, and July 31, 2024.
• Amounts due to related parties increased significantly to $1,121,053 as of July 31, 2025, from $424,654 in 2024.

Risks

• BriaPro Shares are not currently listed on any stock exchange, and there is no assurance of future listing, implying high investment risk and lack of liquidity.
• Future sales or issuances of securities may cause substantial dilution to existing shareholders' voting power and earnings per share.
• The company has a limited operating history since its incorporation on May 15, 2023, and no operating revenues.
• Lack of extensive clinical data to support the clinical effectiveness and safety of any of BriaPro's developmental products.
• The anticipated market for potential products and technologies is unproven, and assumptions about market existence and expansion may be incorrect.
• Anticipated business growth is expected to place significant strain on managerial, operational, and technical resources.
• Significant reliance on third parties for manufacturing, pharmaceutical development, marketing, and management of multi-center clinical trials.
• Pre-clinical studies and initial clinical trials are not necessarily predictive of future results, and favorable early results may not be repeated in later trials.
• Inability to obtain raw materials or product supply from single-source suppliers could cause substantial delays or program termination.
• Must obtain additional capital to continue operations, with no assurance of adequate financing on reasonable or acceptable terms.
• Highly dependent on a few key personnel, and the loss of their services could have a material adverse effect on the business.
• Potential conflicts of interest for directors and officers who are also involved in BriaCell or other biotechnology companies.
• No history of earnings or return on investment, and no plans to pay dividends for some time in the future.
• Existing and proposed changes in laws and regulations affecting public companies may cause increased costs and compliance challenges.
• No independent operating history, with estimates of future cash flows based on combined operations with BriaCell.
• Market perception of early-stage companies may change, potentially affecting the value of holdings and the ability to raise further funds.
• Operations may be subject to governmental laws or regulations, with potential for fines or increased costs for compliance.
• Privacy and data protection laws and regulations (e.g., HIPAA, GDPR) may increase operational costs and expose the company to civil and criminal sanctions.
• Data security breaches could harm the business, expose the company to liabilities, and result in adverse publicity.
• Inherent risk of product liability suits as drug candidates enter clinical trials and commercialization, potentially leading to substantial liabilities.
• Third-party license risk, including the availability and cost of necessary licenses and potential for royalty payments reducing profits.
• Failure to comply with intellectual property or license agreements could lead to termination of rights and hinder commercialization.
• Reliance on the Transition Services Agreement with BriaCell, with risks if the agreement is found to be invalid, unenforceable, or terminated.
• BriaCell's significant majority shareholder position (66.67%) allows it to exercise influence over matters requiring shareholder approval.
• Inflation has the potential to adversely affect the business by increasing overall cost structure.
• Management may identify material weaknesses in internal accounting controls, which could result in material misstatements and failure to meet reporting obligations.
• Government price controls and other restrictions on pricing, reimbursement, and access to drugs may affect future revenues and profitability.
• Intellectual property litigation is common in the biotechnology industry, with uncertain outcomes, high costs, and potential for patent invalidation.
• Steps taken to protect intellectual property (patents, confidentiality agreements) may be inadequate against unauthorized disclosure or infringement.
• Need to initiate lawsuits to protect or enforce patents and other intellectual property rights, which can be expensive, time-consuming, and unpredictable.
• Damage resulting from claims that employees or contractors have inadvertently used or disclosed trade secrets of former employers.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time, leading to competition from generics or biosimilars.
• Operations are subject to human error, which could result in significant uninsured losses.
• Difficulty in enforcing judgments and effecting service of process on directors and officers residing outside Canada.
• Litigation, even if successful, can redirect significant resources and create a negative perception of the business.
• Insurance coverage may be inadequate or unavailable for all risks and hazards to which the company is exposed.
• Negative impact from adverse or inaccurate information posted on social media platforms.

Future Outlook

BriaPro expects to screen several different Bria-TILsRx multi-specific binding reagents for activity in vitro and in mouse models of cancer over the next year, aiming to select at least one candidate for IND enabling studies. Human clinical studies for Bria-TILsRx are projected to begin in the first half of 2027, contingent on securing funding. In parallel, the company plans to select and optimize novel protein kinase C delta inhibitors, with human clinical studies expected to commence in the second half of 2026. Anti-B7-H3 antibodies are also slated for development as antibody drug conjugates (ADC), with IND enabling studies anticipated when funding becomes available. The company expects operating expenses and staffing levels to increase and anticipates incurring further losses through the completion of research and development.

Management Comments

• "The Company expects to incur further losses through to the completion of the research and development of any therapy; the nature of a development stage immune-oncology company requires the raising of financial capital to support its clinical development programs and administrative costs."
• "The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources."
• "Until the Company raises additional financing, it is entirely dependent on BriaCell to finance the Companys operations."
• "BriaPro believes that by partnering with experts in the field it has a competitive advantage to develop selective and potent PKC inhibitors."
• "The TILsRx program embodies a new concept to selectively target cancer cells. It bears risks such as that true cancer-selectivity may not be achievable, but has high potential as a new, potentially first-in-class drug platform."

Industry Context

BriaPro operates within the highly competitive global cancer immunotherapy market, which was estimated at $115 billion in 2022. The company is strategically leveraging artificial intelligence (AI) in drug discovery, a rapidly growing sector projected to expand from USD 1.5 billion in 2023 to USD 20.30 billion by 2030, with a CAGR of 29.7%. Its Bria-TILsRx platform aims to innovate beyond existing bi-specific T cell engagers (BiTEs) by offering quadrivalent binding and blocking multiple immune checkpoints. The PKC inhibitor program targets RAS transformed tumors, which represent a significant portion of human malignancies, indicating a focus on a broad and impactful area of cancer treatment.

Comparison to Industry Standards

• BriaPro's quadrivalent Bria-TILsRx platform is designed to enhance specific targeting of tumor cells and potent activation of T cells, aiming to surpass the limitations of current bi-specific T cell engagers (BiTEs) like BLINCYTO (for leukemia) and IMDELLTRA (for lung cancer) which are restricted by available cancer cell targets.
• The company's anti-B7-H3 antibody was designed and shown to have superior target-binding potential compared to an anti-B7-H3 antibody developed and tested in the clinic by other entities.
• BriaPro is developing novel PKC inhibitors in a field management believes is stalled regarding isoform-selectivity, aiming to gain a competitive advantage through partnerships with experts.
• The global cancer immunotherapy market, estimated at $115 billion in 2022, highlights a large but competitive landscape where BriaPro seeks to differentiate through novel approaches and AI-driven drug discovery.
• The use of AI in drug discovery, a market projected to reach USD 20.30 billion by 2030, positions BriaPro as an early competitor in a rapidly expanding and innovative sector, contrasting with traditional drug discovery methods.

Corporate Governance

Related Party Transactions

• As of July 31, 2025, $1,121,053 is owed to BriaCell group companies, comprising fixed monthly services of $460,000 and direct expenses of $661,053 paid by BriaCell on behalf of BriaPro.
• During the year ended July 31, 2025, the company incurred Services and direct expense paid for by BriaCell in the amount of $696,399.
• BriaPro is entirely dependent on BriaCell to finance its operations until additional financing is raised.
• A Transition Services Agreement was executed on August 31, 2023, with BriaCell, where BriaCell provides certain research and development and head office services for a fixed monthly fee of $20,000.
• BriaCell beneficially owns or controls approximately 31,963,452 common shares, representing 2/3rd of the issued and outstanding common shares of BriaPro.
• A Licensing Agreement dated March 16, 2017, exists between Faller & Williams Technology LLC (FWT) and Sapientia Pharmaceuticals, Inc. (a subsidiary of BriaCell whose assets were transferred to BriaPro), involving milestone payments and royalties to FWT for licensed patents.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future capital raises, potential loss of entire investment due to going concern uncertainty, no immediate liquidity for BriaPro shares, and no history of earnings or dividends.
• **Employees/Management:** Dependence on key personnel, potential strain on managerial resources due to anticipated growth, and potential conflicts of interest for those also involved with BriaCell.
• **Creditors:** Increased 'Due to related parties' balance ($1,121,053 owed to BriaCell), negative working capital, and going concern uncertainty pose risks to repayment.
• **Customers (future):** Potential for novel and more effective cancer therapies if development is successful, but also risks of unproven market and product liability.
• **Suppliers/Contractors:** Reliance on third-party suppliers and contract research organizations (CROs) for raw materials, manufacturing, and R&D, with inherent risks of supply chain disruption.

Next Steps

• Screen several different Bria-TILsRx multi-specific binding reagents for activity in vitro and in mouse models of cancer over the next year.
• Select at least one Bria-TILsRx candidate to advance into IND enabling studies.
• Initiate human clinical studies for Bria-TILsRx in the first half of 2027, pending funding.
• Select novel protein kinase C delta inhibitors, optimize structures, and advance to the candidates selection stage.
• Initiate human clinical studies for PKC inhibitors in the second half of 2026.
• Develop anti-B7-H3 antibodies as antibody drug conjugates (ADC), with IND enabling studies expected to begin when funding is available.
• Raise additional funds for animal studies, including efficacy experiments in mice and toxicology/pharmacokinetics studies needed for Investigational New Drug applications.
• Transition services from BriaCell to its own internal organization or alternate third-party providers as promptly as practicable.
• Assess the impact of IFRS 9 clarification amendments (effective January 1, 2026) and IFRS 18 (effective January 1, 2027) on financial statements.

Key Dates

Recommendation

BriaPro Therapeutics is an early-stage, pre-clinical company with no revenue, significant and increasing losses, and a substantial accumulated deficit. The auditors have highlighted a material uncertainty regarding its ability to continue as a going concern, and it is entirely dependent on its parent company, BriaCell, for financing. While the pipeline shows potential, the immediate financial instability and high operational risks, coupled with the need for substantial future capital raises that will dilute existing shareholders, make it a high-risk investment with a very uncertain path to profitability. The current financial position suggests a strong likelihood of further capital erosion.

Keywords

Immuno-oncology, Bria-TILsRx, PKC inhibitors, B7-H3 antibodies, Cancer therapy, Pre-clinical development, Biotechnology, Drug discovery, Artificial intelligence, Patent application, Financial results, Going concern, BriaPro Therapeutics, BriaCell Therapeutics